✦ LIBER ✦

Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: Results from an 18-month international multi-center phase 3 trial

✍ Scribed by Gordon K. Wilcock; Sandra E. Black; Alfred H. Balch; David A. Amato; Andrew P. Beelen; Lon S. Schneider; Robert C. Green; Edward A. Swabb; Kenton H. Zavitz

Book ID: 118465274
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 121 KB
Volume: 5
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2009.05.220

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O3-04-01: Safety and efficacy of tarenfl

O3-04-01: Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: Results from an 18-month multi-center phase 3 trial

✍ Robert C. Green; Lon S. Schneider; Suzanne B. Hendrix; Kenton H. Zavitz; Edward 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Efficacy and Safety of Intravenous Solan

Efficacy and Safety of Intravenous Solanezumab in Patients with Mild to Moderate Alzheimer's Disease: Results of Two Phase 3 Studies

✍ Hake, Ann M.; Siemers, Eric; Carlson, Christopher; Estergard, Wahiba; Sundell, K 📂 Article 📅 2013 🏛 American Psychiatric Publishing Inc 🌐 English ⚖ 50 KB

Safety, tolerability, and preliminary ef

Safety, tolerability, and preliminary efficacy of SAM-531, a 5HT-6 antagonist, in subjects with mild-to-moderate Alzheimer's disease: Results from a phase 2a study

✍ Claudine Brisard; Beth Safirstein; Kevin Booth; Lisa Hua; Yves Brault; Sangeeta 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 43 KB

A phase 3, randomized, double-blind, pla

A phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in patients with Gaucher disease type 1 (ENGAGE): Results after 9months of treatment

✍ Mistry, Pramod; Lukina, Elena; Dridi, Marie-Françoise Ben; Amato, Dominick; Bari 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 77 KB